Conferences

Catalog

Abstracts

Calendar

2026 San Francisco Lung Cancer Conference

Accreditation: 4.50 AMA PRA Category 1 Credit™ | 4.50 Nursing Contact Hours | 4.50 ABIM MOC II | 4.50 ACPE Pharmacy

Venue: Hyatt Regency San Francisco Downtown SOMA, 50 3rd Street, San Francisco, CA, United States

Start Date: May 16, 2026

Registration Closed

Overview

Trusted by Thousands of Attendees
Across Our Events

49+

Email if you have questions

Our Speakers

Planning Committee

Binay Shah, MD, MHA

Conference Director

Binayatara

Millie Das, MD

Conference Chair

Stanford University/VA Palo Alto

Dron Gauchan, MD

Conference Chair

Sutter Medical Group

Matthew Gubens, MD

Conference Chair

University of California, San Francisco

Faculty

Mohana Roy, MD

Session Chair

Stanford University

Ranjan Pathak, MD

Session Chair

Enloe Health

Tianhong Li, MD, PhD

Session Chair

UC Davis Health

Rajwanth Veluswamy, MD

Session Chair

Nathaniel James Myall, MD

Topic Presenter

Stanford Cancer Center

Jacqueline Aredo, MD

Topic Presenter

Stanford Cancer Institute

Robert Chun-Hao Hsu, MD

Topic Presenter

USC Norris Comprehensive Cancer Center, University of Southern California

Sterling Humphrey, MD

Topic Presenter

Sutter Medical Group and Sutter Cancer Center

Kevin Lu, MD

Topic Presenter

Arta M Monjazeb, MD, PhD

Topic Presenter

UC Davis

Shiruyeh Schokrpur, MD, PhD

Topic Presenter

UC Davis Health

Tyiesha Brown, MD

Case Presenter

Ryan Quinton, MD, PhD

Case Presenter

Deepti Behl, MD

Faculty

Collin Blakely, MD

Faculty

University of California San Francisco

Greg Allen

Faculty

Kim-son Nguyen, MD

Faculty

Sutter Health

Sid Devarakonda, MD

Faculty

Our Agenda

Saturday, May 16th, 2026

All timings are in Pacific Time (PDT, GMT-07:00) time.

07:00 AM - 08:00 AMRegistration, Breakfast, & Exhibits (Gallery Foyer)

08:00 AM - 08:05 AMWelcome & Opening Remarks (Gallery II)

08:05 AM - 09:35 AMSession 1: Progress in Targeted Therapy (Gallery II)

Session Chair: Dron Gauchan, MD

08:05 AM - 08:20 AM

Application of Targeted Therapy in early stage NSCLC – Collin Blakely, MD

08:20 AM - 08:35 AM

Optimal Sequencing of Therapy in EGFR Mutant NSCLC – Deepti Behl, MD

08:35 AM - 08:50 AM

Targeting HER2 in NSCLC – Nathaniel James Myall, MD

08:50 AM - 09:05 AM

EGFR Exon 20 ins & Uncommon Mutations in NSCLC – Sid Devarakonda, MD

09:05 AM - 09:20 AM

Targeting Other Uncommon Oncogene Drivers – Mohana Roy, MD

09:20 AM - 09:35 AM

Case Discussion – Jacqueline Aredo, MD

09:35 AM - 10:20 AMSession 2: New Targets & Treatments in Oncogene Driven Lung Cancer (Gallery II)

Session Chair: Mohana Roy, MD; Ranjan Pathak, MD

09:35 AM - 09:50 AM

Evolution of ALK and ROS1 Treatments in Lung Cancer – Tianhong Li, MD, PhD

09:50 AM - 10:05 AM

Next Generation KRAS Inhibitors – Robert Chun-Hao Hsu, MD

10:05 AM - 10:20 AM

Case Discussion – Tyiesha Brown, MD

10:20 AM - 11:05 AMBreak & Product Theatre: Immunotherapy in Practice: A Compelling Case-Based Discussion Examining Actual Patients with Advanced NSCLC - sponsored by Regeneron. Speaker: Dr. Edgardo Santos, MD, FACP, FASCO (Salon II) (Non CME Accredited)

11:05 AM - 12:20 PMSession 3: Immunotherapy & ADCs in Advanced Lung Cancer (Gallery II)

Session Chair: Tianhong Li, MD, PhD

11:05 AM - 11:20 AM

Early stage immunotherapy – Dron Gauchan, MD

11:20 AM - 11:35 AM

New Biomarkers & Role of MRD – Arta M Monjazeb, MD, PhD

11:35 AM - 11:50 AM

ADCs in Lung Cancer – Kim-son Nguyen, MD

11:50 AM - 12:05 PM

Novel IO Agents in NSCLC – Greg Allen

12:05 PM - 12:20 PM

Case Discussion – Kevin Lu, MD; Sterling Humphrey, MD

12:20 PM - 01:20 PMLunch & Product Threatre: The First and Only DLL3-Targeting Bispecific T-cell Engager (BiTE®) Therapy for 2L ES-SCLC - sponsored by Amgen. Speaker: Siamak Saadat, MD, City of Hope – Colton (Salon II) (Non- CME accredited)

01:20 PM - 01:50 PMIndustry Forum: Shared Decision-Making in the Management of Treatment-Related Toxicities for EGFR-Mutated NSCLC (non - CME accredited)

Session Chair: Rajwanth Veluswamy, MD

01:50 PM - 02:20 PMBinaytara's Efforts in Improving Cancer Care Disparities (Gallery II)

02:20 PM - 03:20 PMSession 4: Latest & Greatest in Squamous Lung Cancer, SCLC, and Thymoma/Mesothelioma (Gallery II)

Session Chair: Millie Das, MD

02:20 PM - 02:35 PM

Advances in SCLC – Millie Das, MD

02:35 PM - 02:50 PM

Treatment of Thymic Malignancies & Mesothelioma – Matthew Gubens, MD

02:50 PM - 03:05 PM

New Targets in Squamous NSCLC – Shiruyeh Schokrpur, MD, PhD

03:05 PM - 03:20 PM

Case Discussion – Ryan Quinton, MD, PhD

03:20 PM - 03:20 PMAdjourn

Acknowledgement of Commercial Support

This activity is supported with an Independent Medical Education grant from Gilead Sciences.

About 2026 San Francisco Lung Cancer Conference

Overview

Faculty and committee

Our Speakers

Planning Committee

Faculty

Conference program and agenda

Our Agenda

Venue and map

Accreditations and continuing education

Acknowledgement of Commercial Support

Registration and pricing

Exhibitors and sponsorship

Our Speakers

Planning Committee

Faculty

Our Agenda

Acknowledgement of Commercial Support